Cridanimod MedChemExpress (MCE)

Product Name	9-Oxo-10(9H)-acridineacetic acid
Synonyms	10-CMA XBIO-101 Cridanimod Cridanimod sodium Aridone acetic acid Acridone Acetic Acid N-(Carboxymethyl)-9-acridone Synonyms 10-CMA XBIO-101 Cridanimod Cridanimod sodium Aridone acetic acid Acridone Acetic Acid N-(Carboxymethyl)-9-acridone 10-CARBOXYMETHYL-9-ACRIDANONE 10-carboxymethyl-9-acridanone 9-Oxo-10(9H)-acridineacetic acid 10-Carboxymethylacridin-9(10H)-one (9-Oxo-10(9H)-acridinyl)acetic acid (9-oxoacridin-10(9H)-yl)acetic acid 9-Oxo-9,10-dihydro-10-acridineacetic acid
CAS	38609-97-1
EINECS	634-833-1
Chemical Formula	C15H11NO3
Molecular Weight	253.25
inchi	InChI=1/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)
Package	10 mM * 1 mL;5 mg;10 mg
Price	Email to quote
Descriptions	Cridanimod Cridanimod MedChemExpress (MCE) HY-W011890 38609-97-1 99.93% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US Descriptions Cridanimod Cridanimod MedChemExpress (MCE) HY-W011890 38609-97-1 99.93% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer. Cridanimod (IM 1-6 mg twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in mice in a dose-dependent manner[1]. PR, IFNα, IFNβ[1] In Vivo Cridanimod (IM 1-6 mg twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in mice in a dose-dependent manner[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Athymic mice with hec50co cells[1] \| \| \| \| \| \| \| \| \| \| [1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact